The clinical outcomes of 114 patients with atrial fibrillation who had been treated with the innovator propafenone, and in whom the drug was then replaced with generic propafenone because of cost containment, were compared. The generic formulation was found to be at least as safe and effective as the innovator drug, with regard to atrial fibrillation recurrence, emergency room and hospital admissions, and necessity for concomitant therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.amjcard.2004.02.071 | DOI Listing |
Publication Analysis
Top Keywords
atrial fibrillation
12
innovator propafenone
8
generic formulation
8
patients atrial
8
efficacy substituting
4
substituting innovator
4
propafenone generic
4
formulation patients
4
fibrillation clinical
4
clinical outcomes
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!